1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Malignant Neoplasms - Pipeline Review, H2 2013

Malignant Neoplasms - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 46 pages

Malignant Neoplasms - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Malignant Neoplasms - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Malignant Neoplasms, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Neoplasms. Malignant Neoplasms - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Malignant Neoplasms.
- A review of the Malignant Neoplasms products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Malignant Neoplasms pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Malignant Neoplasms.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Malignant Neoplasms pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Malignant Neoplasms - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Malignant Neoplasms Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Malignant Neoplasms 7
Malignant Neoplasms Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Malignant Neoplasms Therapeutics - Products under Development by Companies 13
Companies Involved in Malignant Neoplasms Therapeutics Development 14
Shionogi and Co., Ltd. 14
Sanofi-Aventis 15
Novartis AG 16
Enzon Pharmaceuticals, Inc. 17
Antisense Pharma GmbH 18
INNOPHARMAX, INC. 19
Etubics Corporation 20
Malignant Neoplasms - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
firtecan pegol - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
AP-11014 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
SAR-405838 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
S-222611 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
ETBX-011 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
LDK-378 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
NCE For Neoplasms - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
gemcitabine hydrochloride Oral - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Malignant Neoplasms Therapeutics - Drug Profile Updates 38
Malignant Neoplasms Therapeutics - Discontinued Products 43
Malignant Neoplasms Therapeutics - Dormant Products 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables

Number of Products Under Development for Malignant Neoplasms, H2 2013 7
Products under Development for Malignant Neoplasms - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Clinical Stage Development, H2 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Shionogi and Co., Ltd., H2 2013 14
Sanofi-Aventis, H2 2013 15
Novartis AG, H2 2013 16
Enzon Pharmaceuticals, Inc., H2 2013 17
Antisense Pharma GmbH, H2 2013 18
INNOPHARMAX, INC., H2 2013 19
Etubics Corporation, H2 2013 20
Assessment by Monotherapy Products, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 25
Malignant Neoplasms Therapeutics - Drug Profile Updates 38
Malignant Neoplasms Therapeutics - Discontinued Products 43
Malignant Neoplasms Therapeutics - Dormant Products 44

List of Figures

Number of Products under Development for Malignant Neoplasms, H2 2013 7
Products under Development for Malignant Neoplasms - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Early Clinical Stage Products, H2 2013 11
Discovery and Pre-Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 21
Assessment by Route of Administration, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Molecule Type, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone ...

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.